These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38099867)

  • 21. Identification of the high-risk patient for ovarian hyperstimulation syndrome.
    Papanikolaou EG; Humaidan P; Polyzos NP; Tarlatzis B
    Semin Reprod Med; 2010 Nov; 28(6):458-62. PubMed ID: 21082503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited.
    Zarek SM; Muasher SJ
    Fertil Steril; 2011 Jun; 95(8):2449-55. PubMed ID: 21550037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of ovarian hyperstimulation syndrome: novel strategies.
    Grudzinskas JG; Egbase PE
    Hum Reprod; 1998 Aug; 13(8):2051-3. PubMed ID: 9756266
    [No Abstract]   [Full Text] [Related]  

  • 24. Thrombophilia and ovarian hyperstimulation syndrome: a case report.
    Levy G; Lucidi RS
    Hawaii Med J; 2011 May; 70(5):97-8. PubMed ID: 21857739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Controlled ovarian hyperstimulation in an in vitro fertilization program. Results and prevention of complications].
    Grochowski D
    Ginekol Pol; 2000 Oct; 71(10):1293-6. PubMed ID: 11143940
    [No Abstract]   [Full Text] [Related]  

  • 26. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
    Mourad S; Brown J; Farquhar C
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012103. PubMed ID: 28111738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANZCOG CREI Consensus Statement on treatment of Ovarian Hyperstimulation Syndrome.
    Kwik M; Karia S; Boothroyd C
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):413-9. PubMed ID: 26279582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we eliminate severe ovarian hyperstimulation syndrome? Not completely.
    Buckett W; Chian RC; Tan SL
    Hum Reprod; 2005 Aug; 20(8):2367; author reply 2367-8. PubMed ID: 16024544
    [No Abstract]   [Full Text] [Related]  

  • 29. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
    Balen AH; Morley LC; Misso M; Franks S; Legro RS; Wijeyaratne CN; Stener-Victorin E; Fauser BC; Norman RJ; Teede H
    Hum Reprod Update; 2016 Nov; 22(6):687-708. PubMed ID: 27511809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights in prediction of ovarian hyperstimulation syndrome.
    Kasum M; Oresković S
    Acta Clin Croat; 2011 Jun; 50(2):281-8. PubMed ID: 22263397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee.
    Tan BK; Mathur R
    Hum Fertil (Camb); 2013 Sep; 16(3):151-9. PubMed ID: 23705784
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention and management of ovarian hyperstimulation syndrome.
    Chen CD; Chen SU; Yang YS
    Best Pract Res Clin Obstet Gynaecol; 2012 Dec; 26(6):817-27. PubMed ID: 22647872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
    Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can we eliminate severe ovarian hyperstimulation syndrome? Comment 2.
    De Neubourg D; Gerris J
    Hum Reprod; 2005 Aug; 20(8):2369; author reply 2369-70. PubMed ID: 16024547
    [No Abstract]   [Full Text] [Related]  

  • 35. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
    Weiss NS; Kostova E; Nahuis M; Mol BWJ; van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010290. PubMed ID: 30648738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence.
    Martinez MC; Ruiz FJ; García-Velasco JA
    Curr Drug Targets; 2013 Jul; 14(8):843-9. PubMed ID: 23614678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome.
    Lee KH; Kim SH; Jee BC; Kim YJ; Suh CS; Kim KC; Lee WD
    Fertil Steril; 2010 May; 93(7):2274-80. PubMed ID: 19249755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ovarian hyperstimulation syndrome--a risk of treatment for infertility].
    Bangsbøll S
    Nord Med; 1997 Sep; 112(7):236-9. PubMed ID: 9380489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quadruplet pregnancy complicated by ovarian hyperstimulation syndrome with spontaneous ovulation.
    Sugaya S; Hiroi T
    Clin Exp Obstet Gynecol; 2012; 39(3):402-4. PubMed ID: 23157058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jul; 34(7):616-622. PubMed ID: 29334275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.